시장보고서
상품코드
1485028

항암제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 적응증별, 약물별, 투여 경로별, 최종 사용자별, 지역별, 경쟁사별(2019-2029년)

Anticancer Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Drug, By Route of Administration, By End User, By Region and Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 184 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

항암제 세계 시장 규모는 2023년 1,725억 2,000만 달러로 평가되었고, 2029년까지 연평균 5.25%의 꾸준한 성장이 예상됩니다.

암은 여전히 전 세계적으로 수백만 명의 생명을 앗아가는 건강 문제입니다. 효과적인 치료법을 찾기 위한 끊임없는 노력의 일환으로 세계 항암제 시장은 중요한 기업로 부상하고 있습니다. 이 시장은 획기적인 연구와 기술 발전에 힘입어 암 치료제의 전망을 형성하는 데 매우 중요한 역할을 하고 있습니다. 세계 항암제 시장은 고령화, 라이프스타일의 변화, 암에 대한 인식 증가 등의 요인으로 인해 최근 몇 년동안 괄목할 만한 성장세를 보이고 있습니다. 다양한 시장 보고서에 따르면, 시장은 앞으로도 상승세를 유지하며 수익과 기술 혁신 측면에서 새로운 고지에 도달할 것으로 예상됩니다. 면역 치료는 암 치료의 판도를 바꾸는 기술로 등장했습니다. 면역관문억제제, 키메라 항원 수용체(CAR) T세포 치료와 같은 치료법이 널리 받아들여지고 있습니다. 이 시장에서는 치료 효과를 높이고 부작용을 줄이기 위해 새로운 면역치료제 연구개발에 대한 투자가 증가하고 있습니다.

시장 개요
예측 기간 2025-2029년
시장 규모 : 2023년 1,725억 2,000만 달러
시장 규모 : 2029년 2,125억 5,000만 달러
CAGR : 2024-2029년 5.25%
급성장 부문 유방암
최대 시장 북미

정밀의료의 시대는 암 치료에 패러다임의 전환을 가져왔습니다. 환자의 유전적 체질과 암의 분자적 특징에 따라 치료법을 조정하는 것이 점점 더 보편화되고 있습니다. 이러한 개별화된 접근법은 치료 성적을 향상시킬 뿐만 아니라 부작용을 최소화할 수 있습니다. 표적 치료는 항암제 개발의 초점이 되고 있습니다. 암의 성장과 진행에 관여하는 특정 분자를 표적으로 삼도록 설계된 저분자 억제제와 단일 클론 항체가 큰 성공을 거두고 있습니다. 시장은 다양한 암종에 대한 표적치료제 개발이 급증하고 있습니다.

주요 시장 성장 촉진요인

암 발병률 증가

연구 개발 투자 증가

주요 시장 과제

의약품 개발 비용의 상승

주요 시장 동향

기술의 발전

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 항암제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 적응증별(유방암, 혈액암, 전립선암, 소화기암, 부인과암, 폐암, 기타)
    • 약제별(세포 독성제, 호르몬 요법, 표적치료, 기타)
    • 투여 경로별(경구, 비경구, 기타)
    • 최종사용자별(병원 및 진료소, 외래 진료 센터, 기타)
    • 지역별
    • 기업별(2023년)
  • 시장 맵

제5장 아시아태평양의 항암제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 적응증별
    • 약제별
    • 투여 경로별
    • 최종사용자별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 호주
    • 일본
    • 한국

제6장 유럽의 항암제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 적응증별
    • 약제별
    • 투여 경로별
    • 최종사용자별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 스페인
    • 이탈리아
    • 영국

제7장 북미의 항암제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 적응증별
    • 약제별
    • 투여 경로별
    • 최종사용자별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제8장 남미의 항암제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 적응증별
    • 약제별
    • 투여 경로별
    • 최종사용자별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제9장 중동 및 아프리카의 항암제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 적응증별
    • 약제별
    • 투여 경로별
    • 최종사용자별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제10장 시장 역학

  • 성장 촉진요인
  • 과제

제11장 시장 동향과 발전

  • 최근 동향
  • 제품 출시
  • 인수합병(M&A)

제12장 세계의 항암제 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

  • 의약품 업계 경쟁
  • 신규 참여 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제14장 경쟁 구도

  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
  • Eli Lilly and Company(India) Pvt. Ltd.
  • AstraZeneca plc
  • Sanofi S.A.
  • Bayer AG

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH 24.06.03

Global Anticancer Drug Market was valued at USD 172.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. Cancer remains a formidable global health challenge, affecting millions of lives annually. In the relentless pursuit of effective treatment options, the global anticancer drug market has emerged as a critical player. This market, fueled by groundbreaking research and technological advancements, plays a pivotal role in shaping the landscape of cancer therapeutics. The global anticancer drug market has witnessed significant growth in recent years, driven by factors such as an aging population, lifestyle changes, and increased awareness of cancer. According to various market reports, the market is expected to continue its upward trajectory, reaching new heights in terms of both revenue and innovation. Immunotherapy has emerged as a game-changer in cancer treatment. Therapies such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapies have gained widespread acceptance. The market is witnessing increased investment in research and development for novel immunotherapeutic agents, aiming to enhance treatment efficacy and reduce side effects.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 172.52 Billion
Market Size 2029USD 212.55 Billion
CAGR 2024-20295.25%
Fastest Growing SegmentBreast Cancer
Largest MarketNorth America

The era of precision medicine has brought about a paradigm shift in cancer treatment. Tailoring therapies based on a patient's genetic makeup and the molecular characteristics of their cancer has become increasingly common. This personalized approach not only improves treatment outcomes but also minimizes adverse effects. Targeted therapies continue to be a focal point in anticancer drug development. Small molecule inhibitors and monoclonal antibodies designed to target specific molecules involved in cancer growth and progression have demonstrated significant success. The market is witnessing a surge in the development of targeted therapies across various cancer types.

Key Market Drivers

Increasing Cancer Incidence

In recent years, the global healthcare landscape has been grappling with an alarming surge in cancer incidence. This rise in cancer cases has prompted an unprecedented demand for advanced and effective anticancer drugs. As the world faces the challenges posed by the increasing prevalence of cancer, the pharmaceutical industry is stepping up its efforts to develop innovative therapies, driving the growth of the global anticancer drug market. Cancer continues to be a major public health concern, with millions of new cases diagnosed each year across the globe. Several factors contribute to the escalating rates of cancer. Lifestyle choices such as tobacco use, unhealthy diets, lack of physical activity, and exposure to environmental carcinogens play a significant role. An aging population, with an increased life expectancy, contributes to a higher prevalence of cancer.

Increased Investment in Research and Development

The global anticancer drug market has witnessed significant growth in recent years, due to a surge in research and development (R&D) investments dedicated to combating the complex and challenging realm of cancer. As scientists delve deeper into understanding the intricacies of cancer biology, new therapeutic approaches are emerging, leading to the development of innovative anticancer drugs. The increased investment in R&D is a driving force behind the development of novel anticancer drugs. Pharmaceutical companies are allocating substantial budgets to support groundbreaking research initiatives, enabling the exploration of diverse therapeutic avenues. This influx of funds has allowed researchers to pursue innovative strategies, including targeted therapies, immunotherapies, and precision medicine tailored to individual patient profiles. Targeted therapies have emerged as a game-changer in the field of cancer treatment. These drugs are designed to specifically target cancer cells, sparing healthy cells and minimizing side effects. The development of targeted therapies is intricately linked to the understanding of molecular and genetic abnormalities driving cancer growth. R&D investments have enabled scientists to identify and exploit these abnormalities, leading to the creation of drugs that interfere with specific cancer-promoting mechanisms.

Immunotherapy has gained prominence as a revolutionary approach to cancer treatment. By leveraging the body's immune system to recognize and destroy cancer cells, immunotherapies have shown remarkable efficacy in certain cancer types. Research investments have fueled the development of immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapies, and cancer vaccines, providing new hope for patients with previously limited treatment options. Precision medicine represents a paradigm shift in cancer treatment, emphasizing the customization of therapies based on a patient's unique genetic and molecular profile. R&D investments have facilitated the identification of biomarkers and the development of diagnostic tools that enable oncologists to match patients with the most effective treatments. This personalized approach enhances treatment outcomes and reduces the likelihood of adverse reactions. The impact of increased R&D investments is not confined to a specific region but reverberates globally. Collaborations between academic institutions, pharmaceutical companies, and research organizations across borders are fostering a collaborative environment that accelerates progress. As a result, patients worldwide are gaining access to cutting-edge anticancer therapies, contributing to a more equitable distribution of advanced medical interventions.

Key Market Challenges

Rising Costs of Drug Development

The process of developing a new anticancer drug is lengthy, complex, and expensive. It typically begins with extensive preclinical research, where potential compounds are tested in laboratories to assess their safety and efficacy. This phase alone requires substantial financial investment in personnel, equipment, and facilities. Following successful preclinical studies, drugs move to clinical trials, which are conducted in multiple phases involving human subjects. These trials are not only time-consuming but also expensive, with costs skyrocketing due to the need for large patient populations, extensive monitoring, and adherence to rigorous regulatory standards. According to estimates, it can take over a decade and cost billions of dollars to bring a single drug from discovery to market approval.

Stringent regulatory standards set by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) add another layer of complexity and cost to the drug development process. Meeting these standards is essential for ensuring the safety and efficacy of anticancer drugs, but the associated compliance efforts demand substantial financial resources. As the understanding of cancer biology advances, regulatory requirements for demonstrating clinical benefit become more demanding. This evolution contributes to an increase in the size and duration of clinical trials, further elevating the overall costs of drug development. The pharmaceutical industry operates in a high-risk environment where a significant percentage of drug candidates fail at various stages of development. The risks associated with drug development, coupled with the prolonged timelines and escalating costs, can deter potential investors. This risk aversion may lead to fewer resources being allocated to anticancer drug research and development, ultimately limiting the number of new therapies entering the market.

The rising costs of drug development have a direct impact on the pricing of anticancer drugs. Pharmaceutical companies often pass on the expenses incurred during the development process to end-users, including patients, healthcare providers, and payers. As a result, the affordability of these life-saving medications becomes a concern, and access to innovative therapies may be restricted, particularly in lower-income regions.

Key Market Trends

Technological Advancements

In recent years, the field of oncology has witnessed a paradigm shift in the way cancer is diagnosed and treated, due to rapid advancements in technology. The global anticancer drug market is experiencing a transformative phase, with innovative technologies playing a pivotal role in shaping the future of cancer therapeutics. From precision medicine and targeted therapies to artificial intelligence (AI) and immunotherapy, these technological breakthroughs are not only improving patient outcomes but also driving significant growth in the global anticancer drug market. One of the key drivers behind the growth of the global anticancer drug market is the advent of precision medicine and targeted therapies. Traditional chemotherapy often led to collateral damage, affecting both cancerous and healthy cells. However, precision medicine allows for a more personalized approach, taking into account the unique genetic makeup of an individual's cancer. This approach enables oncologists to prescribe drugs that specifically target the molecular and genetic abnormalities driving the growth of cancer cells.

The rise of genomics and next-generation sequencing technologies has empowered researchers to identify specific genetic mutations associated with various types of cancer. Pharmaceutical companies are increasingly developing drugs that target these specific mutations, leading to more effective and less toxic treatment options. As a result, the market for targeted anticancer therapies is expanding rapidly, providing patients with more tailored and efficient treatment regimens.

Artificial intelligence is revolutionizing drug discovery and development, significantly accelerating the identification and optimization of potential anticancer compounds. Machine learning algorithms can analyze vast datasets, including genomic information, clinical trial data, and drug interactions, to identify novel drug candidates and predict their efficacy. AI is also playing a crucial role in drug repurposing, identifying existing drugs that could be repurposed for anticancer purposes. This approach not only saves time and resources but also expedites the availability of new treatment options. The integration of AI in drug discovery is fostering innovation and efficiency in the development of anticancer drugs, contributing to the overall growth of the market.

Early and accurate diagnosis is essential for effective cancer treatment. Recent technological advancements in diagnostic imaging, liquid biopsy, and molecular diagnostics have improved the precision and speed of cancer diagnosis. Liquid biopsy, for example, allows for the detection of circulating tumor DNA in a patient's blood, providing a non-invasive method for monitoring cancer progression and treatment response. Advanced imaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), offer more detailed and accurate visualization of tumors, aiding in treatment planning and monitoring.

Segmental Insights

Indication Insights

Based on indication, breast cancer emerged as the fastest growing segment in the global market for Anticancer Drug in 2023. Breast cancer persists as a significant global health concern, impacting millions of women and, in rare instances, men. The escalating occurrence of risk elements like aging, hormonal shifts, and lifestyle determinants has fueled the upsurge in breast cancer cases. Its prominence in the worldwide anticancer pharmaceutical market stems from its pervasive prevalence and the ongoing endeavors to devise improved and precision-targeted treatments. Pharmaceutical enterprises have acknowledged the substantial market prospects and have made substantial investments in research and development to introduce pioneering therapies for individuals affected by breast cancer.

End User Insights

Based on end user, the Hospitals & Clinics segment is projected to experience rapid growth in the Global Anticancer Drug Market during the forecast period. Hospitals and clinics are actively involved in collaborations with pharmaceutical companies and research institutions to advance the development of novel anticancer drugs. Clinical trials conducted in hospital settings play a crucial role in evaluating the safety and efficacy of new therapies, contributing valuable data to the global anticancer drug market. These collaborations facilitate the seamless integration of research and clinical practice, fostering an environment of innovation in cancer treatment. Patients benefit from access to cutting-edge therapies, and healthcare providers gain insights that contribute to ongoing advancements in the field.

Regional Insights

Based on region, North America emerged as the dominant region in the Global Anticancer Drug Market in 2023, holding the largest market share in terms of value. North America, particularly the United States, has a well-established reputation for leading advancements in pharmaceutical research and development. The region hosts numerous top-tier research institutions, biotechnology companies, and pharmaceutical giants that invest significantly in developing cutting-edge anticancer drugs. The collaboration between academia, private enterprises, and government agencies has created a fertile ground for innovation, leading to the discovery of novel therapies. The United States Food and Drug Administration (FDA) plays a pivotal role in the global pharmaceutical landscape. Its stringent yet efficient regulatory processes ensure that only safe and effective drugs enter the market. The FDA's approval is often seen as a gold standard globally, giving North American pharmaceutical companies a competitive edge. This regulatory framework has facilitated the timely approval and market launch of several groundbreaking anticancer drugs, reinforcing the region's dominance.

Key Market Players

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

Novartis AG

Pfizer Inc.

Bristol-Myers Squibb Company

GlaxoSmithKline plc.

Eli Lilly and Company (India) Pvt. Ltd.

AstraZeneca plc

Sanofi S.A.

Bayer AG

Report Scope:

In this report, the Global Anticancer Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anticancer Drug Market, By Indication:

    Breast Cancer Blood Cancer Prostate Cancer Gastrointestinal Cancer Gynaecologic Cancer Lung Cancer Others

Anticancer Drug Market, By Drug:

    Cytotoxics Hormonal Therapy Targeted Therapy Others

Anticancer Drug Market, By Route of Administration:

    Oral Parenteral Others

Anticancer Drug Market, By End User:

    Hospitals & Clinics Ambulatory Care Centers Others

Anticancer Drug Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anticancer Drug Market.

Available Customizations:

Global Anticancer Drug Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Drug Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Anticancer Drug Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Indication (Breast Cancer, Blood Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer, Others)
    • 4.2.2. By Drug (Cytotoxics, Hormonal Therapy, Targeted Therapy, Others)
    • 4.2.3. By Route of Administration (Oral, Parenteral, Others)
    • 4.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 4.2.5. By Region
    • 4.2.6. By Company (2023)
  • 4.3. Market Map

5. Asia Pacific Anticancer Drug Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication
    • 5.2.2. By Drug
    • 5.2.3. By Route of Administration
    • 5.2.4. By End User
    • 5.2.5. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Anticancer Drug Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Indication
        • 5.3.1.2.2. By Drug
        • 5.3.1.2.3. By Route of Administration
        • 5.3.1.2.4. By End User
    • 5.3.2. India Anticancer Drug Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Indication
        • 5.3.2.2.2. By Drug
        • 5.3.2.2.3. By Route of Administration
        • 5.3.2.2.4. By End User
    • 5.3.3. Australia Anticancer Drug Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Indication
        • 5.3.3.2.2. By Drug
        • 5.3.3.2.3. By Route of Administration
        • 5.3.3.2.4. By End User
    • 5.3.4. Japan Anticancer Drug Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Indication
        • 5.3.4.2.2. By Drug
        • 5.3.4.2.3. By Route of Administration
        • 5.3.4.2.4. By End User
    • 5.3.5. South Korea Anticancer Drug Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Indication
        • 5.3.5.2.2. By Drug
        • 5.3.5.2.3. By Route of Administration
        • 5.3.5.2.4. By End User

6. Europe Anticancer Drug Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Drug
    • 6.2.3. By Route of Administration
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Anticancer Drug Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Drug
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By End User
    • 6.3.2. Germany Anticancer Drug Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Drug
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By End User
    • 6.3.3. Spain Anticancer Drug Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Drug
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By End User
    • 6.3.4. Italy Anticancer Drug Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Indication
        • 6.3.4.2.2. By Drug
        • 6.3.4.2.3. By Route of Administration
        • 6.3.4.2.4. By End User
    • 6.3.5. United Kingdom Anticancer Drug Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Indication
        • 6.3.5.2.2. By Drug
        • 6.3.5.2.3. By Route of Administration
        • 6.3.5.2.4. By End User

7. North America Anticancer Drug Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Drug
    • 7.2.3. By Route of Administration
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Anticancer Drug Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Drug
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By End User
    • 7.3.2. Mexico Anticancer Drug Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Drug
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By End User
    • 7.3.3. Canada Anticancer Drug Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Drug
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By End User

8. South America Anticancer Drug Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Drug
    • 8.2.3. By Route of Administration
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Anticancer Drug Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Drug
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By End User
    • 8.3.2. Argentina Anticancer Drug Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Drug
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By End User
    • 8.3.3. Colombia Anticancer Drug Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Drug
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By End User

9. Middle East and Africa Anticancer Drug Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Drug
    • 9.2.3. By Route of Administration
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Anticancer Drug Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Drug
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By End User
    • 9.3.2. Saudi Arabia Anticancer Drug Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Drug
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By End User
    • 9.3.3. UAE Anticancer Drug Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Drug
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By End User

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Anticancer Drug Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Drug
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. F. Hoffmann-La Roche Ltd.
    • 14.1.1. Company Snapshot
    • 14.1.2. Product & Services
    • 14.1.3. Financials (In case of listed)
    • 14.1.4. Recent Developments
    • 14.1.5. SWOT Analysis
  • 14.2. Genentech, Inc.
  • 14.3. Novartis AG
  • 14.4. Pfizer Inc.
  • 14.5. Bristol-Myers Squibb Company
  • 14.6. GlaxoSmithKline plc.
  • 14.7. Eli Lilly and Company (India) Pvt. Ltd.
  • 14.8. AstraZeneca plc
  • 14.9. Sanofi S.A.
  • 14.10.Bayer AG

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제